Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01111058 · ClinicalTrials.gov registry record · Phase 2
Everolimus Versus Placebo in Head and Neck Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01111058 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 52 participants.
The verdict
NCT01111058, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.
Interventions
- OTHER Placebo
- DRUG Everolimus (RAD 001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-04 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01111058
The ClinicalTrials.gov registry entry for NCT01111058 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01111058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01111058 about?
NCT01111058 is a clinical study titled "Everolimus Versus Placebo in Head and Neck Cancer". Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.
What is the current status of trial NCT01111058?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-04. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01111058?
The interventions under investigation include: Placebo (OTHER), Everolimus (RAD 001) (DRUG).
Who is sponsoring clinical trial NCT01111058?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.